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Introduction
Much of what will be discussed in this
paper can be referred to as drug metabolism,
or drug-metabolizing systems and some fac-
tors which affect these systems, for example
by causing enzyme induction. If such terms
as "drug metabolism" and "enzyme induc-
tion" are not further defined and explained,
many people will still know what I am talk-
ing about and referring to. However, this
sloppy language may needlessly restrict the
interest and importance of some of the
research going on in this field. Attempts to
overcome this language-semantics barrier
have been partly successful and need to be
refined and extended. Some points needing
emphasis in my opinion are: (a) drug metab-
olizing systems have a number of substrates
that are not drugs. Some of these are
"normal" substrates such as steroids, fatty
acids, vitamins, and hormones. Other sub-
strates include chemicals that are present in
our food (such as preservatives, coloring
agents, food additives for taste, odor control
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and other purposes), or water (such as chem-
icals used in purifying the water or pollu-
tants that cannot be removed), or air (odors,
perfumes, and particulates-some added
deliberately, some we can't or don't remove)
and which we ingest in the process of living
and working in an environment increasingly
filled with effectors of these enzyme sys-
tems. To replace "drug metabolizing en-
zymes" with "xenobiotic or foreign chemical
metabolizing systems" recognizes part of the
problem-some of the substrates of these
enzymes are not drugs; (b) drug or xeno-
biotic metabolizing systems can cause acti-
vation and inactivation of chemicals-
sometimes even in sequence with or on the
same substrate. Thus, changes in activity of
the drug or xenobiotic metabolizing systems
can either increase or decrease the toxicity
of chemicals serving as substrates of these
systems. Such changes can be specific for
one substrate or apply to several substrates
and at the same time may make one sub-
strate more toxic and another less so. What
often determines toxicity and actions of a
chemical is the balance between metabolism
to toxic vs. less-toxic metabolites. This
balance may be shifted by increasing any or
all of these metabolisms or by increasing
some more than others, as well as by the
October 1972 55simpler examples of increasing one- kind
(toxication) of reaction and decreasing
another (detoxication) or vice versa. Thus,
two points come out-drug or xenobiotic
metabolizing systems are not just "detoxi-
cation mechanisms" and increases or induc-
tion of these systems can lead at the same
or different times to intoxication as well as
detoxication relative to the "before induc-
tion" stage; (c) toxication-detoxication sys-
tems include many reactions that are not
oxidative in nature, are not cytochrome
P450 requiring, are not restricted to the
liver, and can occur elsewhere than in the
microsomes. Therefore, to talk only about
hepatic microsomal drug oxidations and
further to consider only those which involve
cytochrome P450 is to talk about a very
small (but vigorously and intensely studied)
part of the body's systems for metabolizing
endogenous and exogenous chemicals.
One cannot really deal with these three
problem areas merely by recycling the
nomenclature. Yet our use of convenient but
inexact items can, by repetition, cause some
dulling of our appreciation of the problems
we are making for ourselves and colleagues
in other disciplines who need to inform us
and vice versa about common research
efforts with these systems. People who work
on "drug metabolizing enzyme systems" will
tend to use drugs as substrates and think of
the systems primarily in terms of their roles
in therapeutics. Scientists who study "xeno-
biotic metabolizing systems" will think
largely in terms of non-drug substrates and
perhaps concentrate on the role of these
systems and their interactions with model
substrates, industrial chemicals or environ-
mental pollutants. Research on "steroid or
fatty acid metabolizing systems" will tend to
focus on the role of these enzymes in regu-
lating homonal functions and body homeo-
stasis. Studies on "vitamin and non-steroid
hormone metabolisms" will often concern
itself with nutritional balances, intermediary
metabolism and similar systems. The point
being that words do make a difference,
labels do matter, and we ignore this human
weakness with some costs attached. One can
throw up his hands in despair at this point
since alternatives to "drug metabolizing
enzymes" are not easy to sell to anyone, let
alone think up. But the lack of viable alter-
natives has led to a lot of "clubs" who do
not communicate well with each other and
the whole subject suffers. I will now close
this part of the introduction by choosing my
label for these systems: toxication-
detoxication systems, only wishing I could
somehow also add: ... that may use as
substrates drugs, foreign chemicals, or endog-
enous lipid-class members such as steroids,
fatty acids, and vitamins, or endogenous
non-lipids like thyroxine, and certain amines
(even epinephrine or precursors), and may
even be systems that neither toxify nor
detoxify, but rather only metabolize these
various substrates, and whose metabolism
can be characterized as oxidative and non-
oxidative, synthetic and hydrolytic, involving
many organs besides liver, and including a
lot of non-cytochrome P450 dependent
systems.
Having spent so much time on broadening
perspectives, I must now hasten to assure
the reader that I cannot possibly deal with
all these matters in this paper. Indeed the
main subjects covered will be few in number
and terribly selective since I prefer to write
about my own work and not that of others.
This will not be a general review of drug or
xenobiotic metabolism, since I think plenty
of these already exist. Instead, I wish to
write about three research projects that have
been under study in my laboratory over the
last few years, and which I feel are of rele-
vance to the interface between "drug"
metabolism and environmental health science
as disciplines having identity problems that
are not dissimilar. These research projects I
wish to concentrate on are: (a) extrahepatic
toxication-detoxication systems; (b) age-
dependent changes in toxication-detoxication
systems in lung vs. liver, and (c) species-
strain-individual differences in "induction" of
hepatic toxication-detoxication systems by
the pollutants benzpyrene and DDT.
If the reader wishes a general review of
"drug metabolism," or even specifically drug
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health, he should read elsewhere. Several
very good reviews of the subject of "drug
metabolism" and selected aspects of the
systems in liver, especially those requiring
cytochrome P450 have appeared quite
recently. Some of these reviews are in book
form; others are in journals or monographs.
Many conferences are being held on the
subject and the conference proceedings often
appear very shortly thereafter. I cannot
begin to list all such "reviews" that have
been published even in the last 3 or 4 years.
Inevitably, I would leave a key reference
out, and probably that of a good friend.
Having thus dusted off a few old griev-
ances and given you some idea of what I
will say and will not even attempt to do, I
can now turn to my subject with a some-
what less guilty conscience.
Extrahepatic Toxication-Detoxication Systems
The major research efforts in the field of
"drug-metabolizing enzymes" have been con-
cerned with systems in the liver. It is true
that the liver of most animal species studied
is especially rich in enzyme systems that
metabolize chemicals of all kinds. It is also
true that most workers have been aware that
other body tissues had the ability to metab-
olize chemicals, but the reasons for the rel-
ative lack of studies of these other organs
are numerous and probably include: (a) ease
of handling the tissue - isolating it for study
in vivo and in vitro as in perfused organ
systems, slices, homogenates, and subcellular
fractions - few tissues can match liver in
manipulability for experimental study at all
these levels of organization; (b) hetero-
geneity of structure - irregularities of blood
flow or supply, lobular architecture or
similar organ area differences, number of
different cell types - the liver is almost
ideally homogeneous, having relatively uni-
form lobules, and only two or three major
cell types which can now be separated from
each other for further study if desired; (c)
ability to detect and quantify the metabo-
lizing systems of interest - problems in quan-
tifying low levels of component or enzyme
activity especially in the presence of high
blanks due to things like blood - the liver
has high levels of most toxication-
detoxication systems and contaminants or
inhibitors of assays can often be removed
easily or at least lowered by perfusion,
washing, etc.; (d) stability of systems - prob-
lems in preparing components or enzyme
systems for assay before they are lost by
cytolysis or autolysis, problems in storage of
systems (freezing), problems in long-time
incubation especially with low enzyme activi-
ties - the liver decomposes slowly, stores well,
and is stable for most incubation or assay
periods especially since content or enzyme
activity is so high; (e) quantity of tissue
available vs. quantity of tissue needed for
assay, statistics, etc. - high activity and plenty
of homogeneous tissue makes liver almost
ideal in experiments calling for repetitive
sampling or biopsy, estimation of individual
variability, purification of the enzyme
systems, etc.
Early studies in "drug metabolism" did
occasionally include comparisons of liver
with other tissues, at least in the common
laboratory animals. From such studies it was
learned that most organs of excretion or
exchange were likely to have at least some
capacity to metabolize chemicals. However,
it was also obvious from this early work that
in most cases, the variety of toxication-
detoxication systems was certainly much less
in extrahepatic tissues (than in liver), their
activities (or levels) were often barely quan-
tifiable and likely to be highly variable in
"amount" from one species to another and
even one animal to another - seemingly
much more so than with liver. From time to
time publications have appeared dealing with
the metabolism of compound "X" by some
extrahepatic tissue. Few if any studies have
attempted to characterize the "drug metabo-
lizing systems" of extrahepatic tissues in
anything like the way done with liver.
Among the problems that seemed to be
rather consistently overlooked were: (a)
Does the perfused whole organ metabolize
the drug or remove it from blood by bind-
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Do slices of the organ metabolize the drug
(or store it, or excrete it)?; (c) What might
be the activity of drug-metabolizing enzymes
in homogenates and subcellular fractions
(mitochondria, nuclei, lysosomes, micro-
somes, soluble fraction) and how does this
compare (per gram organ) with activity in
slices or in whole perfused organ?; (d) Have
these subfractions of the homogenate been
characterized by electron microscopy and
biochemical markers?; (e) How great a prob-
lem is created by having many different cell
types in the organ - which of these cell
types are active in drug metabolism?; (f)
Have a variety of substrates been used, and
have enzyme assays been optimized with
respect to protein dependence, substrate
concentration, pH and cofactor requirements,
ionic strength, etc.?; (g) What kinds of en-
dogenous inhibitors or activators may be
present in vivo vs. in vitro and can these
inhibitors or activators be removed and iso-
lated for study?; (h) What are the species,
strain, sex, and individual variations seen in
whether these systems are present (or ab-
sent) and what is the variation in level of
activity of these extrahepatic systems in vivo
and in vitro? What is the role of genetics vs.
environment in the control of these vari-
ances?
Among tissues of obvious relevance to
problems of environmental pharmacology
and toxicology are those at the portals of
entry or contact between ourselves and our
environment. Metabolism of chemicals at
such entrances or contact spots could be
most important to the action of these chem-
icals - leading to activation or fixation of the
chemical at its site of metabolism, or detoxi-
cation and excretion of the chemical.
Among the first organs that we sought to
characterize with respect to toxication-
detoxication systems, and to compare these
with the analogous liver systems, was the
lung. We were aware of the fact that lung
had been shown to have some ability to
metabolize chemicals and that animals
seemed to differ widely with respect to
levels of toxication-detoxication systems in
lung. We chose to study metabolizing sys-
tems in rabbit lung since this animal has
high levels of several "drug metabolizing
enzymes" in its lung, and the mass of tissue
per animal made it more likely that we
could study systems in individual animals
(1). There was also a system to study drug
metabolism in an isolated perfused lung (2).
Our first studies were concerned with
characterizing various treatments of lung to
obtain homogenates, and then with the iso-
lation from such homogenates of repre-
sentative fractions such as nuclei, mito-
chondria, and microsomes. We hoped to
identify these subcellular fractions on the
basis of marker enzyme activities, using
markers that were regarded as highly specific
for the analogous hepatic fractions.
A major problem arises just in getting a
reasonably good homogenate of lung tissue.
The compromise needed is between rupture
of at least a significant fraction of the cells
and extensive fragmentation of particulates
like mitochondria. We obtained what we
consider to be a reasonable approach to such
a compromise by just mincing the tissue
extensively with an ordinary meat grinder or
tissue press, and then homogenizing in a
teflon-glass Potter homogenizer. The homog-
enate resulting from such manipulation can
then be subfractionated into nuclei, mito-
chondria, microsomes and soluble fractions,
though the correspondence of these lung
fractions with analogously prepared liver
fractions may not be too exact. There seems
to be much less cell disruption in the case of
lung than liver and a greater degree of cross-
contamination as seen both in electron
micrographs of the fractions and in terms of
marker enzymes. Especially interesting was
the finding of a meshwork in the lung
microsomal fractions; this mesh seemed to
tie together several microsomal vesicles and
ribosomal particles into a kind of clump. We
believe the presence of such a meshwork will
make study of lung microsomal subfractions
especially difficult. Thus, liver microsomes
can be subfractionated into several types
rough-surfaced vs. smooth-surfaced (3-11) as
well as further subdivisions of each of these
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magnesium binding vs. non-binding types
of smooth-surfaced membranes (12, 13)).
These microsomal subfractions in liver can
be relatively pure (by electron microscopy)
and contain differing amounts of drug-
metabolizing enzymes. Similar studies
applied to the lung could be misleading
unless some way is found to break up the
meshwork found in the microsomal frac-
tions. At present, we are studying the use of
sonication to break up these meshworks and
we find that sonication helps to increase the
yield of microsomes per gram liver and lung
and the percentage of a microsomal marker
enzyme (benzphetamine demethylase) which
is recovered in the microsomal fraction of
liver and lung. For example, of the total
benzphetamine demethylase activity in the
unsonicated homogenate, we find 60-80% of
this in the microsomal fractions prepared
from liver homogenates but only 20-25% of
it in the microsomes from lung homogenate.
When the homogenates are sonicated even
briefly (10 secs-30 secs), the recoveries of
activity in microsomes are markedly in-
creased at least in lung. Thus in liver, recov-
eries range from 80-100% of homogenate
activity in microsomes while in lung from
50-75% of the homogenate activity is now
present in microsomes (14). This suggests
that sonication is a very useful adjunct to
routine homogenizing for purposes of in-
creasing recovery of microsomes and con-
tents from tissue homogenates. The effects
of sonication were especially marked with
lung and we believe this may result from
effects on the microsomal meshwork.
Our work with marker enzymes and sub-
strates of the toxication-detoxication
systems showed that lung and liver fractions
were similar in many respects. Many of the
"drug-metabolizing" systems were concen-
trated in lung microsomes just as they are in
liver. Major differences between lung and
liver seemed to be (a) glucose-6-phosphatase
was not a good marker for lung microsomes;
(b) glucuronyl transferase activity was not
detectable in lung microsomes; (c) cyto-
chrome b5 and P450 contents of lung micro-
somes were much lower than liver micro-
somes; (d) many "drug metabolisms" were
also much less active in lung than liver
microsomes although some metabolisms were
equally active in microsomes from the two
tissues of the rabbit. These results are found
in a series of publications from our labora-
tory (14-20).
A number of other research projects have
been stimulated by these studies. For one
thing the lung, unlike the liver is quite
heterogeneous - having marked morphol-
ogical differentiations (lobules, bronchi,
alveoli) as well as a plethora of different cell
types. These lung cell types are difficult to
isolate in pure or homogeneous populations.
When we homogenize whole lung we are
sampling a kind of average of all cells in the
lung at the time of death. Since we found
that lung microsomes from such a heter-
ogeneous sample did contain appreciable
levels of toxication-detoxication systems, it
became important to identify which cells
had these systems and whether certain sys-
tems might be found in only a few or even
one kind of cell. Several approaches to this
problem are possible and we hope to use
several of these: (a) histochemical - identify
at least qualitatively and perhaps even semi-
quantitatively where certain of the
toxication-detoxication systems might be
found by applying substrates whose metabo-
lites can be fixed, stained and identified in
tissue sections; (b) separation of cells by
digestion of organ minces with collagenase
hyaluronidase, etc., to liberate cells which
may then be separated on the basis of size,
charge, shape, etc., using gels, electro-
phoresis, centrifugation, etc.; (c) selective
stimulation or inhibition of lung cell growth
- certain factors, diseases, chemicals or
stresses applied to the animal may kill off a
major cell type or cause its proliferation to
markedly change its proportion of the total.
This might be combined with method (b) to
give even better separations for study, pro-
viding the factor, disease, stress or chemical
did not affect cells not stimulated or killed
and did not cause losses of toxication-
detoxication systems even in cells stimulated
October 1972 59to proliferate; (d) growth of cells in culture
or use of lung tumors - this often results in
favoring one cell type over another.
Even before these studies are done, one or
two simple experiments can be tried - for
example lung washouts (lavages) can give cell
populations especially rich in alveolar mac-
rophages. When we subjected such cells to
analysis for toxication-detoxication systems
we found little if any detectable (20). Thus
at least one of the major cell types in lungs
contributing to the lung microsomal fraction
is not a storehouse or site of concentration
of toxication-detoxication systems.
Age-Dependent Changes in Toxication-Detoxication
Systems in Lung vs. Liver
The newborn of several animal species are
relatively deficient in the hepatic microsomal
"drug metabolizing" enzyme systems. Such a
defect probably contributes to the relative
sensitivity of the newborn (compared to
adults) to the actions and toxicities of a
number of chemicals and drugs that are
detoxified by these systems. I have been
interested in the age-related changes in
toxication-detoxication systems for many
years, with most of my studies dealing with
the liver systems (21-27). Having found lung
to contain appreciable amounts of some
analogous metabolic systems (15-20), we
were interested in how these lung systems
compared with liver during the first month
of life. We were also hoping to see whether
different parts of some of the toxication-
detoxication systems might develop at quite
different rates in liver vs. lung, and to gain
some more insight into whether the rate-
limiting step for certain reactions might be
different in liver vs. lung.
In the rabbit, we found that two general
patterns of development of enzyme activity
and cytochromes seemed to be present: (a) a
slow gradual increase in activity and level
during and beyond the first month of life -
typical of most of the systems in the lung
and (b) a gradual increase to an age of about
2 weeks and then a sudden jump to adult
levels of activity - typical of most systems in
the liver (14).
Another finding of interest was that drug
metabolisms, cytochrome b5 and P450 levels
and activities of NADPH-cytochrome c and
P450 reductases did not correlate well at the
various ages in eigher lung or liver. It was
also obvious that at least in the lung a major
problem would arise in trying to equate the
rate-limiting step of drug metabolism with
the activity of NADPH-cytochrome c reduc-
tase. Various laboratories have tried to
identify the key (rate-limiting) step in cyto-
chrome P450-dependent drug metabolisms in
liver microsomes. At the present time, many
workers believe that for mixed function
oxidases (MFO) in these liver microsomes,
the most likely candidate for this key role is
NADPH-cytochrome P450 reductase (P450
reductase) activity. Thus rates of MFO-
catalyzed detoxication-reactions in liver
microsomes do not correlate well with cyto-
chrome P450 or b5 levels, but do agree
fairly well with P450 reductase levels. Even
better correlation may be found if the P450
reductase activities are measured in the
presence of substrates or other effectors of
the systems, since P450 reductase activity is
affected by substrates (29) and metal ions or
ionic strength (30, 31).
At all ages studied, lung and liver micro-
somes had very similar but age-dependent
levels of NADPH-cytochrome c reductase
and where measurable, NADPH-cytochrome
P450 reductase. Our preliminary studies on
these enzyme activities and their response to
added ions or substrates suggest that the
responses of these enzymes are also similar
in the two organs, at least in the adult
rabbit. We have now studied several sub-
strates of liver vs. lung microsomal
toxication-detoxication systems. Two group-
ings can be made: (a) substrates whose rate
of metabolism per mg microsomal protein
per unit time is the same or greater in lung
than in liver microsomes (benzphetamine
dealkylation, biphenyl hydroxylation, ethyl-
morphine demethylation, or p-chloro-N-
methylaniline demethylation), and; (b) sub-
strates or components whose metabolism or
level per mg protein is much less in lung
than in liver microsomes (benzpyrene
Environmental Health Perspectives 60hydroxylase, aminopyrine demethylase, an-
iline hydroxylase, p-nitrobenzoic acid reduc-
tase, and the cytochromes b5 and P450). If
activity is expressed per nmole P450 per
unit time then nearly all metabolisms in lung
are equal to (group b) or many times greater
(group a) than those in liver.
If NADPH-cytochrome c reductase is the
same enzyme as NADPH-cytochrome P450
reductase (32, 33), and if NADPH-
cytochrome P450 reductase is the rate-
limiting step for MFO's dependent on
cytochrome P450, then it is not a simple
matter to understand how the rate-limiting
steps in lung and liver can be at the same
level while substrate metabolisms such as
benzpyrene hydroxylase, aminopyrine
demethylase, and aniline hydroxylase differ
by factors as great as five-fold in lung vs.
liver. The result is not qualitatively changed
whether activity is expressed per mg protein
or per nmole of P450; the discrepancy is
just as large. But now the question changes:
How can the rate-limiting step in lung be so
much greater than in liver when the metab-
olism of several chemicals (aminopyrine,
aniline, benzpyrene) occurs at the same rate
in the two organs?
Species Differences in Induction of Hepatic
Toxication-Detoxication Systems
by the Pollutants, Benzpyrene and DDT
The hepatic "drug-metabolizing enzyme
systems" can be stimulated by a variety of
chemicals when these are ingested by the
animal. The stimulation usually takes several
hours or days, and seems to involve syn-
thesis of more of these systems. Chemicals
which cause this hepatic enzyme "induc-
tion" can be divided into several classes on
the basis of (a) how soon the increase can
first be detected; (b) whether several micro-
somal systems or components are increased
or only a few; (c) whether the increase is
accompanied by a proliferation of the paren-
chymal cell (smooth) endoplasmic reticulum;
(d) whether cytochrome P450 increases or a
new cytochrome (P1 450, P448) is formed;
(e) whether and how much substrate-
difference spectra (produced by adding
chemicals to microsomal suspensions in a
spectrophotometer cuvette) are affected,
and (f) effects on the kinetic constants of
the drug or chemical metabolisms.
Two classes of hepatic drug-metabolizing
enzyme inducers are well-studied, and
typical members of these classes are benz-
pyrene or 3-methylcholanthrene vs. pheno-
barbital or DDT. The enzyme induction by
benzpyrene can be detected between 6 and
12 hours after animals are treated with benz-
pyrene, whereas stimulation by DDT is de-
tectable only much later; benzpyrene
stimulates only a few enzyme systems while
DDT causes increase in most of the
toxication-detoxication systems in liver
microsomes; benzpyrene does not cause in-
crease in parenchymal cell smooth endo-
plasmic reticulum, whereas DDT usually in-
duces a massive proliferation of this system;
benzpyrene induces the formation of a spec-
trally different P450 (P1450, P448) that can
be purified and shown to behave quite
differently from normal P450, whereas DDT
appears to promote the formation only of
more P450; substrate difference spectra after
benzpyrene seem to be increased only for
those substrates whose metabolism is in-
creased and most other substrate spectra are
decreased or qualitatively changed, whereas
DDT seems to cause only increases in spectra
if any change occurs at all; benzpyrene seems
to decrease Km for those substrates whose
Vmax is increased, whereas DDT affects only
Vmax (per mg microsomal protein). In
reality, DDT probably does not affect even
Vmax, since if expressed per nmole P450,
there is little change in this "constant" as
would be expected if only more, but not
different enzyme is being produced.
Species and strain differences in response
to inducers of hepatic microsomal drug
metabolism have been described, but are not
widely recognized. Such variability in re-
sponse can be very large quantitatively, at
which point it becomes almost qualitative
(one species responding so poorly that for
practical purposes there has been no induc-
tion). Such variability can be important in
explaining different chemical toxicities
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understanding interactions of chemicals or
chemicals-drugs-environmental stresses, etc.
Induction of toxication-detoxication systems
can markedly shift such things as ED50 or
LD50 or even qualitatively change chemical
actions or toxicities.
The basis for these variations in response
to inducers of the hepatic enzyme systems
has been presumed to be both genetic and
environmental, and both have now been
described, though not in great detail.
Whether and how much induction of the
hepatic systems occurs with any given in-
ducer does indeed vary with diet (starvation
vs. diets with abnormal fat content, protein
content, or vitamin content), age of the
animal, time of day (or light-eating cycles),
and presence or absence of other effectors
of these systems (antibiotics, antimetab-
olites, pesticides, disease, stress), and these
factors can be lumped together (with many
others I have not listed) under the general
class of environmental influences. Genetic
control of enzyme induction can be seen in
variations in response to inducers between
sexes (in rats) as well as between individuals,
strains, and species of animals.
Several years ago, we showed that strains
of rabbits differed in response of their he-
patic microsomal enzymes to phenobarbital
administration to the rabbit (34). The dif-
ferences seen involved not only the gener-
ality of whether a given strain seemed to
respond to phenobarbital or not and how
much, but whether a given hepatic drug
metabolism responded in all or only a few
rabbit strains. Among the six strains of rab-
bits, the California and English strains
seemed to be generally less responsive to
phenobarbital than the others, while Jack
rabbits seemed to be more responsive to
phenobarbital ("responsive" defined as total
number of drug metabolisms significantly in-
creased by phenobarbital compared with
total number of drug metabolisms studied).
As far as pathways were concerned, only one
was induced in all strains (hexobarbital ox-
idase) while two were not increased in any
strain (amphetamine deamination and chlor-
promazine sulfoxidation). Other pathways
were increased in some strains, but not
others. Some of these differences may have
been environmentally induced rather than
determined by genetics, since the wild rab-
bits (cottontails, jack rabbits) obviously
could have had quite different diets, etc.,
both before and after delivery to our lab-
oratory (wild rabbits in captivity do not eat,
are highly stressed, etc.).
In later work, we discovered an apparent
difference in response of rats vs. mice to
induction of hepatic toxication-detoxication
systems by benzpyrene and DDT (35-41).
Thus, at doses and schedules of dosing and
at times after last dose of the inducer that
clearly established hepatic microsomal en-
zyme induction by DDT or benzpyrene in
rats and other species including monkeys
(42), the mouse did not show such induc-
tion or showed it only marginally (36). A
detailed study of the mouse liver systems
failed to uncover any evidence for enzyme
induction by benzpyrene (38, 39), although
we were able to show some enzyme induc-
tion by the related, but more potent poly-
cyclic hydrocarbon 3-methylcholanthrene.
Others have reported that mice are less
likely to respond to hepatic microsomal
enzyme inducers of the polycyclic hydro-
carbon class than are other species, espe-
cially rats (43). Most of these other findings
were made using 3-methylcholanthrene as
the inducer, not benzpyrene, and the accu-
mulated evidence began to suggest that we
were dealing with a quantitative, not a qual-
itative difference - mice responded poorly to
an inducer that worked well in rats.
A very similar picture emerged with DDT.
DDT did not affect most mouse liver micro-
somal systems enough for the changes to be
measured, whereas the related inducer, chlor-
dane, could cause quantifiable responses in
mice (35, 36). Again the accumulating evi-
dence suggested a quantitative, not quali-
tative, difference in mouse vs. rat response
to the hepatic enzyme inducers, DDT and
benzpyrene.
However, work done in Dr. Nebert's lab
(44, 45) suggested that mouse strains may
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duction of benzpyrene hydroxylase by poly-
cyclic hydrocarbons. These workers have
shown that inducibility is strain specific and
gene dependent as a simple autosomal dom-
inant trait. Thus the C57BL/6N mouse
responded to inducers of benzpyrene hy-
droxylase, while the DBA/2N mouse did
not. A most interesting result of these exper-
iments was that the "resistant" mouse
(DBA/2N) was able to respond to other
classes of inducers such as phenobarbital.
Also that resistance of benzpyrene hydrox-
ylase to induction applied to extrahepatic
tissues as well as liver. Other polycyclic
hydrocarbons (than 3-MC) were effective or
non-effective in the same way as 3-MC.
Thus, none of these worked in any-tissue of
the DBA/2N mouse, though phenobarbital
could stimulate hepatic drug metabolisms in
this mouse.
Our most recent work with mouse liver
responses to benzpyrene and DDT has used
the same strain of mouse that we started
with at Iowa, i.e., mice which did not re-
spond to benzpyrene, but did respond to
3-methylcholanthrene and very slightly to
DDT. In these latest studies we have greatly
increased the dose of inducer used and
shortened the period between last dose of
inducer and the time of enzyme assay. We
have now been able to show that this strain
of resistant mouse (Swiss-Webster) can re-
spond to benzpyrene and DDT as inducers
of hepatic microsomal enzymes and com-
ponents, but that the induction effect is
very much less and much shorter in duration
than with rats (40, 41). A finding of interest
to us was that even in mice that showed
measurable enzyme response to benzpyrene
treatment, there was still no shift in the
cytochrome P450-CO spectra such as occurs
in other species (due to formation of P1 450
or P448). Nebert and coworkers (44, 45)
have shown that mice responding to 3-
methylcholanthrene treatment (the C57BL
strain) showed a shift from cytochrome
P450 to P448, while mice that didn't re-
spond (by enzyme induction) showed no
P450 to P448 transformation. Our experi-
ments (41) would appear to show that
enzyme induction by benzpyrene in the
Swiss Webster mouse does not require a
synthesis of P448 as is believed necessary by
most people in the field.
One other point may perhaps need em-
phasis before leaving this section. Although
we attempted to use the same strain of mice
in all our studies on DDT and benzpyrene as
inducers in mice vs. rats, we may not have
been able to do so. In the 7 years between
our first reported experiments (35) and our
latest studies (40, 41), it is unlikely that the
Swiss Webster strain of mouse remained
genetically unchanged. Thus, we may well
have started with a mouse genetically unable
to respond to either DDT or benzpyrene,
and ended up with a mouse able to respond
at least to high doses of these inducers. We
hope to continue our studies on genetic con-
trols of response to enzyme induction by
benzpyrene or DDT in the same mouse
strains used by Nebert and coworkers (44,
45).
Conclusion
This paper has considered only a-few of
the many sources of heterogeneity in micro-
somal toxication-detoxication systems and in
the response of these systems to effectors
such as enzyme inducers. It should be
obvious that this heterogeneity has many
bases including both genetic and environ-
mental factors. Few of these have been
sorted out or studied in any detail, and as
we find more of these, it will be increasingly
difficult to isolate only one such effector for
a detailed study. Some of the newer technics
may help us to simplify our experiments so
as to more clearly identify and study single
influencing factors - e.g. - in vitro culture
technics to study enzyme induction on
isolated homogeneous cell populations. It is
unlikely that such simplified systems can
eliminate all multifactorial interactions, but
the approach will be useful regardless.
More important, in my opinion, is a wider
recognition of the heterogeneity of these
systems and their responses. Such recog-
October 1972 63nition could hopefully discourage the gener-
alizations for which overeager problem-
solvers always grasp. It is obvious from
literally thousands of studies that
toxication-detoxication systems are impor-
tant determinants of the action and toxicity
of a wide variety of chemicals, drugs, pollu-
tants, etc. However, it is also becoming
obvious that whether and when these sys-
tems play key roles in determining chemical
effects, how they fluctuate and from what
causes, can very much be almost whimsical
in terms of the fragmentary knowledge we
now possess. Better understanding will hope-
fully generate some more general principles
than we now possess. My purpose in writing
this paper was to emphasize how few gener-
alities we now have and some of the areas
that we have chosen to try to understand
better.
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